Oslo Cancer Cluster is continually monitoring the coronavirus pandemic. The ensuing crisis will have both long- and short term consequences for all parts of our society, including the development of new cancer treatments. We have already noticed some of the effects it has had on health industry, research institutions, cancer hospitals, drug development companies and cancer patients.
This page contains information regarding our activities and useful links for you to stay updated on the COVID-19 situation.
Please get in touch with us if you have any immediate topics you would like us to be aware of.
Oslo Cancer Cluster is following Norwegian government guidelines regarding work routines and gatherings. In adherence to these recommendations, most conferences and networking meetings are cancelled and those that are proceeding are on a purely digital basis. Please consult our event calendar for further information on upcoming meetings.
Oslo Cancer Cluster Incubator Operations
Oslo Cancer Cluster Incubator will have staff on-site, according to a rota. Cleaning protocols to disinfect are in place and will be adapted as needed. We ask all tenants of the Incubator to refrain from inviting any visitors to our facilities for the time being. Please contact the Incubator Team or consult the Interim Guidance Pertaining to Coronavirus/COVID-19 if you have any questions or special requirements.
Connect to the Oslo Cancer Cluster Team
The Norwegian Minister of Health has recommended “Home Office” for larger organizations. All Oslo Cancer Cluster employees will be working from home during this period. If you need to contact us or schedule a meeting, we are available via telephone, e-mail or video conference. Please refer to our Team page for contact details.
We want to hear from you! We are contacting members to seek input about specific challenges and suggestions. The information you provide will help us advocate for member companies in our ongoing dialogue with relevant government agencies. The information will also help us to further connect companies and institutions should they/you be able to assist one another. If there are any immediate topics and input you would like us to be aware of, please contact us any time.
One big challenge for many of our biotech companies is to secure the next capital round from investors. Many cancer companies are now experiencing great uncertainty about the future. We are in a continual dialogue with the Norwegian funding agencies to see how the government can help. In the meantime, please have a look at the links below.
- Inven2 Idéprisen
- Nordic Trial Alliance call for Nordic Covid-19 Activities: Submit your proposal by 15 April 2020.
- NLS Invest: Opportunity for life science start-ups to present to investors at NLSInvest, a pre-event to NLSDays 2020. Deadline for applications is 31 May 2020.
- European Research Area (ERA) Corona Platform: Information on research & innovation in the context of the COVID-19 outbreak
- MERCK Research grant for pandemic preparedness: Research grants for technological solutions towards pandemic outbreak preparedness or solutions that could help fighting emerging viral infections.
- The Research Council of Norway is in dialogue with the Norwegian research environments to prepare different economic measures.
- H2020 webinars The Research Council of Norway are arranging free webinar courses on writing proposals for H2020 funding.
- Innovation Norway has made changes to its regulations for funding and loans.
- SIVA SF is in dialogue with the Norwegian government and other funding bodies to see how to best direct their funding
For updated information and national guidelines on COVID-19, please consult the following websites:
- General information about COVID-19: from Helsenorge.no and Norwegian Institute for Public Health
- National guidelines, regulations and advice: Information from the Norwegian government
- For health professionals and public sector employees: Information from Helsedirektoratet
- For companies: Q&As from the Norwegian government
- For cancer patients, cancer survivors and caregivers: Information from the Norwegian Cancer Society